Amgen Price Target Maintained at $400 as Overvaluation Raises Concerns

Amgen (AMGN) received a reiteration from Cantor Fitzgerald in September 2023, maintaining its Neutral rating and price target of $400.00.

The rating reflects a cautious outlook on Amgen's solid fundamentals, suggesting that the current stock price may not be attractive for new investors.

Amgen is a leading biotechnology company with a market capitalization of approximately $236.38 billion, specializing in human therapeutics and operating within the healthcare sector.

The company's flagship products have established it as a significant player in the drug manufacturing industry.